Related Experiment Video
Updated: Feb 3, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
[Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients]
Naohisa Kusakabe1, Takahiro Osawa1, Haruka Miyata1
1The Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine.
Abstract:
Axitinib was approved for use in Japan as a salvage therapy for patients with metastatic renal cell carcinoma (RCC) in 2012. We retrospectively evaluated the cases of 32 RCC patients that were treated with Axitinib as a 2nd- or further-line therapy between November 2012 and March 2017. Overall survival (OS), progression-free survival (PFS), and adverse events were assessed. The median OS and PFS from the initiation of Axitinib were 29 and 11 months, respectively. Nineteen patients received Axitinib as a 2nd-line treatment, in whom the median OS and median PFS were 22 and 10 months, respectively, while the median OS and PFS were 29 and 15.5 months, respectively, amongthe 13 patients who received Axitinib as a 3rd- or further-line treatment, which suggested that Axitinib is effective in the 3rd-line and further-line settings. A Cox multivariate model revealed that bone metastasis was a significant adverse factor for OS. Common grade 3 or higher adverse events included hypertension (28%), diarrhea (7%), and proteinuria (7%). Although the present study demonstrated the efficacy and safety of salvage Axitinib treatment in patients who had recurrent disease after the initial systemic therapy, further large-scale studies should be warranted to make clear its clinical effectiveness in these patients.
Insights
Axitinib shows effectiveness as a salvage therapy for metastatic renal cell carcinoma (RCC) patients, offering significant overall survival and progression-free survival benefits, especially in later treatment lines.
Area of Science:
- Oncology
- Pharmacology
- Clinical Medicine
Background:
- Axitinib received approval in Japan in 2012 for metastatic renal cell carcinoma (RCC) salvage therapy.
- Metastatic RCC remains a significant challenge, necessitating effective second- or further-line treatment options.
Purpose of the Study:
- To retrospectively evaluate the efficacy and safety of Axitinib as a second- or further-line treatment in Japanese RCC patients.
- To assess overall survival (OS), progression-free survival (PFS), and adverse events associated with salvage Axitinib therapy.
Main Methods:
- Retrospective analysis of 32 RCC patients treated with Axitinib between November 2012 and March 2017.
- Evaluation of OS, PFS, and adverse events, including subgroup analysis for second-line versus third- or further-line treatment.
Main Results:
- Median OS and PFS with Axitinib were 29 and 11 months, respectively.
- Patients receiving Axitinib as third- or further-line therapy showed improved median OS (29 months) and PFS (15.5 months) compared to second-line (OS: 22 months, PFS: 10 months).
- Hypertension (28%), diarrhea (7%), and proteinuria (7%) were common grade 3+ adverse events; bone metastasis was a negative prognostic factor for OS.
Conclusions:
- Salvage Axitinib treatment demonstrates clinical effectiveness and a manageable safety profile in recurrent RCC patients.
- Axitinib appears particularly effective in third-line and further-line settings.
- Larger-scale studies are recommended to further clarify the clinical effectiveness of Axitinib in this patient population.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:13Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
02:24Predicting Reaction Outcomes
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...